@prefix this: . @prefix sub: . @prefix np: . @prefix pav: . @prefix rdf: . @prefix infores: . @prefix xsd: . @prefix umls: . @prefix orcid: . @prefix rdfs: . @prefix biolink: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { umls:C0231918 a biolink:DiseaseOrPhenotypicFeature; rdfs:label "nasal symptoms"; biolink:category biolink:DiseaseOrPhenotypicFeature . a biolink:DiseaseOrPhenotypicFeature; rdfs:label "allergic rhinitis"; biolink:category biolink:DiseaseOrPhenotypicFeature . sub:_1 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_2 rdf:object umls:C0231918; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . } sub:provenance { sub:assertion prov:generatedAtTime "2022-10-13T13:40:02.752577"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627; prov:wasQuotedFrom " OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. The spray is available for adults and adolescents 12 years and 12 years old. The product is available in the US and Europe for $1,800 ($1,300) in the U.S. and Europe. The manufacturer of the product has been approved by FDA and European Patent Patent Company." . biolink: pav:version "2.3.0" . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB"; npx:hasSignature "bzji7lxUQgcFQja9fYKOdaZCUnzVLpt1aEINmkGBxJeOttlBcZBmq7PZ0Xk/+6WwwrxlJ1XEtmFIFila8Lq3u0jaMrtWAeYhr+APGauYLUnah3mXsHBU8LWA09AWe4lWjb/khX6uCbs9BxOdjnd2+x+vouqSg0MTZg6ykZKGpuazjgqewTqZkxilA4RJ4RkMcmIsw90Dip7BpAB/SvDTujBqeVctl7vZpsLEgIsP3EZIfaaL1I4u+kMgSat545chAS636PlY2Nys58rjIh36jmlVmOFRwbXGgXH7UD5T63883aGLqDDd2FIiuop6/f+MTc5uRlPoyhIY3nUFl4Hc1A=="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-10-13T13:40:02.752577"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627 . }